39668-86-5

Basic information

• Product Name: p-menthane-3-carboxylic acid
• Synonyms: p-menthane-3-carboxylic acid;5-Methyl-2-(1-methylethyl)cyclohexanecarboxylic acid;2-Isopropyl-5-methylcyclohexanecarboxylic acid
• CAS NO: 39668-86-5
• Molecular Formula: C₁₁H₂₀O₂
• Molecular Weight: 184.2753
• EINECS: 254-582-8
• Mol File: 39668-86-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 270.9 °C at 760 mmHg
• Flash Point: 131.8 °C
• Appearance: /
• Density: 0.965 g/cm³
• CAS DataBase Reference: p-menthane-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: p-menthane-3-carboxylic acid(39668-86-5)
• EPA Substance Registry System: p-menthane-3-carboxylic acid(39668-86-5)

Safety Data

• Hazardous Substances Data: 39668-86-5(Hazardous Substances Data)

Usage

General Description

p-Menthane-3-carboxylic acid, also known as PM3CA, is a chemical compound belonging to the class of monoterpenoid compounds. It is a derivative of menthol, and is commonly found in peppermint oil. PM3CA has analgesic and anti-inflammatory properties, making it a potential candidate for the development of new pain-relief medications. It has been studied for its potential in treating inflammatory conditions such as arthritis and neuropathic pain. Additionally, PM3CA has shown antioxidant and anti-microbial properties, making it a versatile compound with potential applications in various fields including pharmaceuticals, cosmetics, and food industries.

InChI:InChI=1/C11H20O2/c1-7(2)9-5-4-8(3)6-10(9)11(12)13/h7-10H,4-6H2,1-3H3,(H,12,13)

Upstream product

• 54556-12-6 2-isopropyl-5-methyl-cyclohexanecarbonitrile 
• 124-38-9 carbon dioxide 
• 28953-96-0 2-chloro-1-isopropyl-4-methyl-cyclohexane 
• 39711-79-0 WS-3 
• 15719-64-9 methylammonium carbonate 
• 463-79-6 carbonic-acid 
• 65560-17-0 2-isopropyl-5-methyl-cyclohexanecarboxylic acid amide 

Downstream Products

• 1119711-29-3 (2S,5R)-N-[4-(2-Amino-2-oxoethyl) phenyl]-5-methyl-2-(propan-2-yl)cyclohexanecarboxamide 
• 92371-33-0 DL-Acetoxymethyl-menthyl-⁽³⁾-keton 
• 91637-83-1 DL-Diazomethyl-menthyl-⁽³⁾-keton 
• 92037-60-0 DL-Hydroxymethyl-menthyl-⁽³⁾-keton 
• 91883-21-5 DL-Chlormethyl-(menthyl-3)-keton 
• 1845-44-9 2-isopropyl-5-methyl-cyclohexanecarbaldehyde 
• 39668-87-6 2-isopropyl-5-methylcyclohexanecarbonyl chloride 
• 65560-17-0 2-isopropyl-5-methyl-cyclohexanecarboxylic acid amide 

Relevant articles and documents

Process for preparing alicyclic carboxylic acid compounds

A process for preparing at least one alicyclic carboxylic acid compound by Grignard reaction, the process comprising: reacting magnesium and at least one alicyclic halide compound in at least one solvent to produce at least one alicyclic Grignard reagent;concurrently adding carbon dioxide to the magnesium, the alicyclic halide compound, the solvent, and the alicyclic Grignard reagent, while the alicyclic Grignard reagent is still being produced, to form at least one alicyclic carboxylate magnesium salt; andhydrolyzing the alicyclic carboxylate magnesium salt to form the alicyclic carboxylic acid compound;wherein the alicyclic Grignard reagent and the alicyclic carboxylate magnesium salt are prepared in a one-pot synthesis.

Small-molecule modulators of TRP-P8 activity

Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8 modulators and methods for decreasing viability and/or inhibiting growth of Trp-p8 expressing cells, methods for activating Trp-p8-mediated cation influx, methods for stimulating apoptosis and/or necrosis, and related methods for the treatment of diseases, including cancers such as lung, breast, colon, and/or prostate cancers as well as other diseases, such as benign prostatic hyperplasia, that are associated with Trp-p8 expression.

Synthesis of N-t-butyl-p-menthane-3-carboxamide

This invention provides an efficient two-step reaction sequence for producing N-t-butyl-p-menthane-3-carboxamide. The process involves forming 3-p-menthylmagnesium halide, and reacting the 3-p-menthylmagnesium halide with t-butyl isocyanate to form the product.